Long-term outcomes in 1121 Australian prostate cancer patients treated with definitive radiotherapy

被引：2
作者：
de Leon, Jeremiah F. [1 ]
Kneebone, Andrew [2 ,3 ]
Gebski, Val [3 ,4 ,5 ]
Cross, Shamira [5 ,6 ]
Do, Viet [6 ,7 ,8 ]
Hayden, Amy [5 ,6 ]
Ngo, Diana [7 ]
Sidhom, Mark [7 ,8 ]
Turner, Sandra [3 ,5 ]
机构：
[1] Illawarra Canc Care Ctr, Dept Radiat Oncol, 348 Crown St, Wollongong, NSW 2500, Australia
[2] Northern Sydney Canc Ctr, Sydney, NSW, Australia
[3] Univ Sydney, Sydney, NSW, Australia
[4] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] Westmead Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[6] Nepean Canc Ctr, Sydney, NSW, Australia
[7] Liverpool & Macarthur Canc Therapy Ctr, Sydney, NSW, Australia
[8] Univ New South Wales, Sydney, NSW, Australia
来源：
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY | 2019年 / 63卷 / 01期
关键词：
prostate cancer; radiotherapy; DOSE CONFORMAL RADIOTHERAPY; PHASE-III TRIAL; RADICAL PROSTATECTOMY; RADIATION-THERAPY; ANDROGEN-DEPRIVATION; ESCALATION TRIAL; SURVIVAL; SURGERY; MEN; INTERMEDIATE;
D O I：
10.1111/1754-9485.12797
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Introduction: Optimal definitive treatment of prostate cancer is controversial, especially in high-risk patients. We report the largest prospective cohort of Australian patients treated with radiotherapy for localised prostate cancer. Methods: One thousand, one hundred and twenty-one patients with prostate cancer were prospectively registered and treated to a dose of 70-74 Gy. Patients were classified as low, intermediate or high risk based on PSA, clinical staging and Gleason score. Intermediate-risk patients were treated with 0-6 months of hormonal therapy (ADT) and high-risk patients were offered neoadjuvant and adjuvant ADT. Overall survival (OS) and biochemical relapsefree survival (bNED) were calculated using the Kaplan-Meier method. Results: Median follow-up was 92 months. Eight-year OS and bNED were 78.4% and 68.1% respectively in the entire cohort. OS for the low, intermediate and high-risk groups was 84.5%, 78.4% and 68% respectively. For these risk groups, bNED was 80.3%, 65.7% and 53.7% respectively. In the intermediate and high-risk group, OS and bNED decreased with increasing number of risk factors. Conclusion: Definitive radiotherapy is an effective treatment for prostate cancer, including in high-risk cases.
引用
收藏
页码：116 / 123
页数：8
相关论文
共 50 条
[31]   Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy [J].
M Kamrava ;
A H Kesarwala ;
R A Madan ;
E Lita ;
A Kaushal ;
K-Y Tsang ;
D J Poole ;
S M Steinberg ;
T Ferrara ;
W Dahut ;
J Schlom ;
J L Gulley .
Prostate Cancer and Prostatic Diseases, 2012, 15 :289-295
[32]   Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy [J].
Bao, Alicia ;
Barsky, Andrew R. ;
Maxwell, Russell ;
Bekelman, Justin E. ;
Both, Stefan ;
Christodouleas, John P. ;
Deville, Curtiland ;
Fang, Penny ;
Tochner, Zelig A. ;
Vapiwala, Neha .
INTERNATIONAL JOURNAL OF PARTICLE THERAPY, 2022, 8 (04) :14-24
[33]   Fatigue in Prostate Cancer Survivors Treated With Definitive Radiotherapy and LHRH Analogs [J].
Kyrdalen, Anne E. ;
Dahl, Alv A. ;
Hernes, Eivor ;
Hem, Einar ;
Fossa, Sophie D. .
PROSTATE, 2010, 70 (13) :1480-1489
[34]   Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer [J].
Tamari, Keisuke ;
Oh, Ryoong-Jin ;
Masai, Norihisa ;
Shiomi, Hiroya ;
Otani, Keisuke ;
Suzuki, Osamu ;
Ogawa, Kazuhiko .
ANTICANCER RESEARCH, 2018, 38 (07) :4207-4212
[35]   Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer [J].
Lazo, Antonio ;
de la Torre-Luque, Alejandro ;
Arregui, Gregorio ;
Rivas, Daniel ;
Serradilla, Ana ;
Gomez, Joaquin ;
Jurado, Francisca ;
Isabel Nunez, Maria ;
Lopez, Escarlata .
BIOLOGY-BASEL, 2022, 11 (03)
[36]   Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes [J].
Gonzalez-San Segundo, C. ;
Jove, J. ;
Zapatero, A. ;
Pastor-Peidro, J. ;
Vazquez, M. L. ;
Casana, M. ;
Mengual, J. L. ;
Gomez-Caamano, A. ;
Gomez-Iturriaga, A. ;
Vallejo, C. ;
Henriquez, I ;
Munoz-Garcia, J. L. ;
Clemente, J. ;
Porras, M. ;
Collado, E. ;
Ossola, G. ;
Villafranca, E. ;
Cabeza, M. A. ;
Lopez-Torrecilla, J. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (08) :1044-1051
[37]   Long-term outcomes of hypofractionated radiation therapy in patients with high risk prostate cancer [J].
Bulychkin, P. V. ;
Ekaterinushkin, D. A. ;
Tkachev, S. I. ;
Khachaturyan, A. V. ;
Nayanov, G. B. ;
Ladyko, D. D. ;
Selezneva, T. D. .
ONKOUROLOGIYA, 2024, 20 (01) :60-66
[38]   Long-term clinical outcomes of 538 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and external beam radiotherapy [J].
Lehrich, Brandon M. ;
Ravera, John ;
Mostaghni, Navid ;
Yoshida, Jeffrey ;
Torrey, Robert ;
Baghdassarian, Ruben ;
Gazzaniga, Michael ;
Weinberg, Alan ;
Cu Phan ;
Chalfin, Stuart ;
Barnes, Lucy ;
Mesa, Albert ;
Tokita, Kenneth .
JOURNAL OF RADIATION ONCOLOGY, 2019, 8 (03) :311-321
[39]   Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancer [J].
Kamitani, Nobuhiko ;
Watanabe, Kenta ;
Ikeda, Naoki ;
Kawata, Yujiro ;
Tokiya, Ryoji ;
Hayashi, Takafumi ;
Miyaji, Yoshiyuki ;
Tamada, Tsutomu ;
Katsui, Kuniaki .
JAPANESE JOURNAL OF RADIOLOGY, 2024, 42 (11) :1322-1329
[40]   Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up [J].
Creak, A. ;
Hall, E. ;
Horwich, A. ;
Eeles, R. ;
Khoo, V. ;
Huddart, R. ;
Parker, C. ;
Griffin, C. ;
Bidmead, M. ;
Warrington, J. ;
Dearnaley, D. .
BRITISH JOURNAL OF CANCER, 2013, 109 (03) :651-657
12345